Sign In
Register
Free Annual Reports
•
Free Tools
Dictionary
Investing
Markets
Personal Finance
Active Trading
Forex
Professionals
Tutorials
Video
Simulator
Free Newsletters
Term Of The Day
Yield Elbow
The point on the yield curve indicating the year in which the economy's highest interest rates...
Learn More »
Dictionary
Active Trading
Forex
Technical Analysis
Brokers
Options
Futures
Personal Finance
Retirement
Acronyms
Accounting
Bonds
Buzzwords
Currencies
Economics
Financial Theory
Formulas
Hedge Funds
Insurance
Investor Relations
Laws & Regulations
Mutual Funds
Real Estate
Statistics
Stocks
Taxes
Venture Capital
More News »
Follow The Herd In Trading The Capital Market
If you have ever heard "the trend is your friend" and believed it, you may ...
How Interest Rates Affect The Housing Market
Understand how rate changes can affect home prices, and learn how you can ...
Basic Investment Objectives
You might know about different asset types, but do you know how each type ...
Investing
Investing Basics
Bonds & Fixed Income
Fundamental Analysis
Mutual Funds & ETFs
Economics
Definitions
Articles
Videos
Slideshows
Tutorials
Calculators
FAQs
More Analysis »
Actuant Still Working Through A Lull
Actuant is seeing a significant demand lull in heavy ...
FedEx Not Particularly Expensive, But Analysts Still Too Positive
FedEx is doing better with margins and free cash flow, ...
Will A New Alcatel-Lucent Plan Lead To Better Results?
Alcatel-Lucent's new plan sounds good, but the planning ...
Markets
Analysis & Opinions
ETF Center
Sectors
Chart Advisor
Free Tools
Free Annual Reports
Mining
Public Administration
Utilities
Manufacturing
Education
Transportation
Agriculture & Forestry
Real Estate
Wholesale Trade
More Features »
4 Ways To Take Your Career To The Next Level
Whether you are looking to climb the corporate ladder or go it alone in the financial services sector, ...
4 Reasons Why Your Credit Card Company Thinks Your Card Is Stolen
Find out the most common reasons the bank will fear your credit card has been stolen ... even when it hasn't.
Networking For Financial Professionals: Maintaining A Strong Industry Presence
Find out the most productive methods of networking best suited to ambitious financial professionals.
Can Financial Education Rebuild America’s Economy?
Find out why financial education will help America to re-establish itself as the world's (undisputed) ...
Personal Finance
Life Stages
Credit & Loans
Insurance
Retirement
Home & Auto
Savings
Budgeting
Entrepreneurship
Taxes
Credit Cards
Net Worth
Definitions
Articles
Videos
Slideshows
Tutorials
Calculators
FAQs
More News »
Relative Strength: The Strongest Large-Cap Stocks
With indexes near all-time highs, lots of stocks are looking good, but here ...
Follow The Herd In Trading The Capital Market
If you have ever heard "the trend is your friend" and believed it, you may ...
Market Summary For June 14, 2013
The major U.S. indices had mixed performance this week, after a turbulent ...
Low Expense Top Performing ETFs
A technical look at the four ETFs that rank highest for five-year ...
Active Trading
Fundamentals
Charts & Patterns
Technical Indicators
Trading Strategies
Brokers
Software
Options & Futures
Chart Advisor
Discount Brokers
Definitions
Articles
Videos
Slideshows
Tutorials
Calculators
FAQs
More Forex »
The Hidden Fees In 401(k)s
Learn about the conspicuously disclosed fees that lurk within your 401(k) investments.
The Impact Of Currency Conversions
Will a rising or falling dollar hurt you or your company? In this article we explore ...
Why Is Monsanto Evil, But DuPont Isn't?
Monsanto is perhaps the most-hated company, but competitors like DuPont behave in very ...
Follow The Herd In Trading The Capital Market
If you have ever heard "the trend is your friend" and believed it, you may be a fan of ...
Forex
Forex News
Economic Calendar
Forex Fundamentals
Forex Walkthrough
Forex Strategies
Brokers
Platforms
FX Trader
Free Resources
Definitions
Articles
Videos
Slideshows
Tutorials
Calculators
FAQs
Professionals
Global Professional Exams
FINRA Exams
Canadian Professional Exams
Careers
Continuing Education
Exam Prep Quizzer
Series 3
Series 6
Series 7
Series 9/10
Series 22
Series 24
Series 26
Series 55
Series 63
Series 65
Series 66
CFA Level I
CFA Level II
CFA Level III
CFP
CMT Level I
CMT Level II
CMT Level III
FRM Part I
FRM Part II
ERP
LIFA Level I
CSC
CPH
Free Newsletters
Sign up for our free newsletters and receive weekly news and articles delivered right to your inbox!
Stock Watch Weekly
Forex Weekly
News To Use
Professionals in the Money
Personal Finance
Warren Buffett Watch
Investing Basics
Term Of The Day
Analysis & Opinions
ETF Center
Sectors
Chart Advisor
Free Tools
Free Annual Reports
SANOFI $53.40
-1.16
19/6/2013 04:19 PM |
NYSE
:
SNY
| Industries :
Manufacturing
/
Pharmaceutical and Medicine Manufacturing
Quotes
Charts
Analysis
Options
Historical
Digital Company Profile
Get SNY Trend Analysis
- it has outperformed the S&P 500 by 29%
Partner Headlines
Celgene, Regeneron Get Some Favorable News
Investors Business Daily
Odd, This: Big Pharma On Losing End of Pricing Dispute
YCharts
Regeneron, Alexion Big-Cap Biotechs Sales Seen Rising
Investors Business Daily
$176,000 or $295,00 a Year: Bizarre World of Orphan Drugs
YCharts
Novo Plunges On FDA Action
Investors Business Daily
Celgene, Regeneron Get Some Favorable News
Investors Business Daily
Novo Nordisk Hit By Diabetes Drug Delay; Sanofi Rises
Investors Business Daily
FDA Decision on Diabetes Drug Hurts Novo Nordisk, Helps Sanofi
YCharts
Stocks Narrow To Thin Red Line; Generac Backslides
Investors Business Daily
Novo Nordisk Stock Falls, Sanofi Rises On Drug Delay
Investors Business Daily
UPDATE: Regeneron Pharm Announces Receipt of HSR Notice Sanofi to ...
Benzinga
Futures Cut Back Early Advance; Novo Nordisk Tumbles On FDA News
Investors Business Daily
Sanofi Q4 Profit Down 72%
Benzinga
Is My Doctor On the Payroll of Some Drug Maker? Now Easier to Find Out
YCharts
Pay-to-Delay Opponent, FTC Chief Leibowitz, Quits: Respite for Pharma?
YCharts
Novo Nordisk Earnings Beat Views; Competition Looms
Investors Business Daily
My 4 Favorites from Europe's Best Recommended Dividend Stocks
GuruFocus
Novo Nordisk Stock Hits High After Q4 Profit Beat
Investors Business Daily
Time to Hedge Euro Risk?
Benzinga
A Peek Into The Market Before The Trading Starts
Benzinga
Genzyme's LEMTRADA Application for MS Accepted for Review by FDA
Benzinga
Genzyme's LEMTRADA Application for MS Accepted for Review by FDA
Benzinga
2 Attractively Valued Blue Chips
Benzinga
S&P Likes 2 ETFs For Europe's Rebound
Benzinga
Should Johnson & Johnson Unload Troubled McNeil Consumer ...
YCharts
FTC: Pay-to-Delay Pharma Deals Cover $8.3 Billion in Revenue
YCharts
Santarus Wins Drug Approval, Offers Bullish Guidance
Investors Business Daily
Three Stocks to Buy for Flu Season
Benzinga
FDA lowers Ambien dosage
Investors Business Daily
Measuring Social Network Buzz Over Pharma Stocks
YCharts
Ambien, Related Drugs Get Dosage Cut From FDA
Investors Business Daily
How Warren Buffett Made Money with Foreign Stocks
GuruFocus
Medtech Stocks Moving As Conference Makes Waves
Investors Business Daily
Medtech Stocks Moving As Conference Makes Waves
Investors Business Daily
4 Health Care ETFs Your Broker Forgot to Mention
Benzinga
Biogen Stock Falls After ALS Candidate Fails
Investors Business Daily
The 3 Most-Recommended Healthcare Stocks
GuruFocus
16 Really Cheap International Dividend Achievers
GuruFocus
Will Prem Watsa Lose Money on Research In Motion?
GuruFocus
The Bullish Case For French Stocks
GuruFocus
Cell Therapy Might Be Poised For A Comeback
Investors Business Daily
Foreign Drugmakers Holding Up, But Some Have Flaws
Investors Business Daily
Benzinga's Top Upgrades
Benzinga
Dodge & Cox Explain Why They Are Overweight in Pharmaceuticals
GuruFocus
Benzinga's M&A Chatter for Wednesday December 12, 2012
Benzinga
Benzinga's M&A Chatter for Tuesday December 11, 2012
Benzinga
Sanofi Phase II Trial of JAK2 Inhibitor in Myelofibrosis Met ...
Benzinga
Warren Buffett's Best-Yielding Dividend Stocks
GuruFocus
The Other Healthcare Stocks of Warren Buffett
GuruFocus
How Big Pharma Might Get Its R&D Act Together
YCharts
Teva provides weak '13 outlook
Investors Business Daily
Teva's Stock Falls After 2013 Guidance Falls Short
Investors Business Daily
Accenture Life Sciences Study: Worst of Pharma's Patent Cliff is ...
YCharts
Name an Industry That Can Jack Prices Up 13% in This Economy
YCharts
Medical Device Makers: Repeal the New Tax!
FOXBusiness
If Only People Would Take Their Meds – Pharma Sales Might Double
YCharts
Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia
Benzinga
Generics Maker Teva Pharmaceutical to Make Smaller Acquisitions, ...
YCharts
Celgene up after trading bust
Investors Business Daily
Post Downgrade, Say Oui to France?
Benzinga
Celgene, Sanofi, Stryker Up After Inside-Trade Busts
Investors Business Daily
Stocks Rise As Fiscal Cliff Talks Raise Hopes
Investors Business Daily
Stocks Down Modestly; Regeneron Jumps, But Hibbett Slides
Investors Business Daily
From Earlier: CHMP Recommends Granting of Marketing Authorization ...
Benzinga
Big Pharma Gains Another Foe on Pay-to-Delay Deals: 31 State A.G.s ...
YCharts
An Anti-Psychotic Drug With its Own Issues: AstraZeneca's Seroquel ...
YCharts
More Trouble for Big Pharma Stocks: AMA Calls for an End to ...
YCharts
Amgen Cholesterol-Fighter Shows Promise, Shares Rise
Investors Business Daily
China Drug Market to Boom – Diabetes Alone a $3.2 Billion Business ...
YCharts
Sanofi, Regeneron Begin Enrollment in CV Outcomes Trial with PCSK9 ...
Benzinga
Zalicus Prednisporin Licensee Sanofi Provides Update on ...
Benzinga
Making a Cheap Drug Expensive: Sanofi's Efforts in the U.K Draw ...
YCharts
Global Squeeze on Pharma Prices Just Won't Ease Up: Canadians Iffy ...
YCharts
Novo Nordisk Gets EU Nod for Long-Lasting Insulin Drug
FOXBusiness
Ah, Geez, the Aussies, Too? Plush Patent Rights of Big Pharma ...
YCharts
Biogen slides on drug delay
Investors Business Daily
FDA Advisory Committee Votes to Recommend Isis' KYNAMRO
Benzinga
Biogen Stock Slips After FDA Delays MS Drug Review
Investors Business Daily
Pharma Industry Agrees to Price Cuts With Irish Government: More ...
YCharts
Don't Call it Bribery And Whatever it Was, Abbott Stopped Doing ...
YCharts
AAC Technologies Cools Off, Sinopharm Stumbles Higher
Investors Business Daily
One Reason Novartis is Expected to Overtake Pfizer in Revenue: its ...
YCharts
Sanofi's New Cancer Drug Rebuffed by Sloan-Kettering Over Cost; ...
YCharts
Celgene Drug Abraxane OK'd For Lung Cancer; Shares Up
Investors Business Daily
Sanofi's Genzyme to Present New Data from AUBAGIO and LEMTRADATM
Benzinga
Pharma's Pay-to-Delay Deals Boost Healthcare Costs (and Pharma ...
YCharts
Benzinga's M&A Chatter for Thursday October 4, 2012
Benzinga
Sarepta Stock Jumps On Muscular Dystrophy Drug Trial
Investors Business Daily
Sanofi To Buy Genfar
Benzinga
Merck's $1 Billion-a-Year Gardasil Vaccine Garners Another Safety ...
YCharts
The 20 Biggest Healthcare Dividend Payer
GuruFocus
Bad News For Pharma In World's Second-Biggest Market
YCharts
Not So Bad After All For Europe ETFs
Benzinga
What's Pharma R&D Really Producing? Another Take on the Weak Drug ...
YCharts
FDA Approves Genzyme's AUBAGIO Oral Treatment for Relapsing ...
Benzinga
Confused by Pharma Stocks' Hefty Dividends, Weak Drug Pipeline? ...
YCharts
Pharma Trouble: Drug Approvals at FDA Could Slow or Halt Due to ...
YCharts
Seven Cheap Large-Caps Yielding Over 4%
Benzinga
Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)
Benzinga
Stocks Hold Mild Gains; Cheesecake Factory Tops Base
Investors Business Daily
People viewing SNY also viewed:
BIEI
,
SUPN
,
EPZM
,
NRIFF
,
CYCC
,
BZNE
,
OMER
Follow Us:
Marketplace
Follow Markets
Trading Center
Partner Links
Dictionary
Investing
Markets
Personal Finance
Active Trading
Forex
Professionals
Tutorials
Video
Simulator
Free Newsletters
Content Library
Articles
Tutorials
Slideshows
FAQs
Calculators
Chart Advisor
Stock Analysis
Work With Investopedia
License Our Dictionary
Advertise With Us
Email Campaign Deployment
About Our Writers
Write For Us
Contact Us
Careers
Sponsors & Partners
Free Annual Reports
CanDoFinance
Newsletters
Sign up for our FREE e-newsletters
© 2013, Investopedia US, A Division of ValueClick, Inc.
All Rights Reserved
|
Terms Of Use
|
Privacy Policy